News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Full results and Plain Language Summary for CheckMate 77T trial – NEJM
Photo of NEJM from tukuz.com
May 28, 2024, 07:48

Full results and Plain Language Summary for CheckMate 77T trial – NEJM

NEJM shared on X/Twitter:

“In the CheckMate 77T trial, researchers assessed whether adding adjuvant nivolumab to neoadjuvant nivolumab plus chemotherapy would improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Full results and Plain Language Summary.”

Perioperative Nivolumab in Resectable Lung Cancer A PLAIN LANGUAGE SUMMARY Top Figure: Illustration of treatment options during the Neoadjuvant and Adjuvant Periods. Bottom Figure: Graph of the Percentage of Patients with Event-free Survival

Source: NEJM/X

adjuvant nivolumab cancer CheckMate 77T trial NEJM neoadjuvant nivolumab OncoDaily Oncology resectable NSCLC
Special Coverage
Blog
Mar 26, 2025, 16:17
We are proud to announce the renewal of our partnership with the IAEA - City Cancer Challenge
Blog
Mar 26, 2025, 15:47
ESMO has just announced the ESMO Ambassadors for this year’s ELCC - LuCE
Blog
Mar 26, 2025, 15:14
Jessie Yu: Excited for the upcoming BIOCHINA Global Forum in Seoul on September 12th
Blog
Mar 26, 2025, 15:07
1 month left to submit your abstract for SIOG 2025
Blog
Mar 26, 2025, 14:53
Pashtoon Kasi: Different lenses of looking at the same biology
Blog
Mar 26, 2025, 14:43
Tuan Thanh Nguyen: Global survey on disparities in Prostate Cancer care
Science
Mar 26, 2025, 14:35
Oscar Tahuahua: If quitting smoking gave you back 10 yrs, would you believe it?
Blog
Mar 26, 2025, 14:29
Sunil Verma: It was wonderful to visit India and our AstraZeneca India teams there
Science
Mar 26, 2025, 14:26
Yüksel Ürün: Revolution in Metastatic Melanoma
Blog
Mar 26, 2025, 14:18
David Planchard: Take home messages by Fabrice Barlesi on oncogenic treatment of localised NSCLC in 2025
Blog
Mar 26, 2025, 14:11
ECOG-ACRIN Cancer Research Group is now enrolling for EAQ222CD/CostCOM
Science
Mar 26, 2025, 14:03
Nita Radhakrishnan: Cost analysis of thalassemia screening vs treatment in different health care sectors